ArticleJACC. Case reports2025
Tissue Plasminogen Activator to Resolve Elevated Purge System Pressure in a Catheter-Based Ventricular Assist Device.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microaxial Flow Pump Thrombosis Presenting as Predominant Direct Hyperbilirubinemia.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increasing use of percutaneous ventricular assist devices, understanding device-related complications becomes paramount. Although percutaneous ventricular assist devices such as the Impella offer crucial cardiac support, their use can also be associated with rare thrombotic complications. A patient with cardiogenic shock presented with anterior ST-segment elevation myocardial infarction. He had successful primary percutaneous coronary intervention to the left anterior descending artery with Impella support. Post procedure, he was transferred to the intensive care unit where the Impella device was noted to have an elevated purge pressure. Device replacement was not an option; therefore, we used a tissue plasminogen activator-based approach to successfully resolve this issue. This case report discusses an innovative use of tissue plasminogen activator to manage elevated purge pressure in a catheter-based ventricular assist device.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.